Key Highlights

  • Third-quarter sales climbed to USD 1,715.5 million from USD 1,553.1 million, a 10.5% increase, and USD 1,007.6 million of that was generated in the United States.
  • Edwards Lifesciences (NYSE:EW) generated USD 307.5 million of attributable net income, up from USD 291.1 million, and diluted EPS came in at USD 0.53 versus USD 0.50.
  • Mitral and tricuspid transcatheter sales advanced 44.3% to USD 209.5 million, and aortic valve replacement sales grew 8.0% to USD 1,241.6 million.
  • The quarter absorbed a USD 220.2 million charge for impaired intangible and long-lived assets, chiefly because one in-process R&D asset was written off entirely.

Valve Franchises Carry the Top Line

Edwards Lifesciences (NYSE:EW) submitted its Quarterly Report on November 4, 2026, which covers the three months ended September 30. Sales rose 10.5% to USD 1,715.5 million, and the Business outside the United States grew 9.7% to USD 707.9 million. Aortic valve Revenue reached USD 1,241.6 million, a lift tied to the SAPIEN 3 Ultra RESILIA valve. Mitral and tricuspid lines moved up 44.3% on PASCAL, EVOQUE and SAPIEN M3 demand. Surgical sales added 2.5% to USD 264.4 million, led by the INSPIRIS RESILIA, KONECT RESILIA and MITRIS RESILIA valves. Europe climbed 6.9% to USD 414.6 million and Japan 2.2% to USD 92.0 million, and Rest of World was the fastest regional gainer at 20.2%. The company calls itself a structural heart disease innovation business, and its growth rests on that franchise.

One-Off Charges Reshape the Quarterly Bottom Line

Several one-time entries shaped the period. The USD 220.2 million Impairment stands against USD 40.0 million in the prior year, while certain litigation items moved from USD 90.4 million of expense to a net insurance recovery of USD 12.7 million. Gross Profit came in at USD 1,346.3 million, a calculated Margin near 78.5% compared with 77.8%, aided by lower Manufacturing spending and a currency tailwind worth 0.5 points. Operating Income fell to USD 299.1 million from USD 307.1 million. Interest income, net, slipped to USD 36.5 million from USD 38.6 million as yields declined, and other non-operating income reached USD 27.6 million versus USD 2.7 million, reflecting gains linked to the Autus and variable interest entity consolidations. The extract does not give an adjusted profit figure, so the underlying quarter cannot be measured without the charge.

Diluted EPS Dips Over Nine Months on Tax and Impairments

Across the first nine months, net sales grew 13.5% to USD 5,105.1 million, but diluted EPS slid to USD 1.61 from USD 1.67. Management blamed a heavier tax bill and impairments, including a USD 163.6 million loss linked to variable interest entity investments. Cash and equivalents ended at USD 3,110.8 million, while Operating Cash Flow of USD 1,266.0 million compared with USD 1,144.3 million a year earlier. The filing identifies Tariff uncertainty as a threat that could lift costs or soften customer demand. Higher headcount and commercial spending pushed selling expenses up, while research spending increased on aortic valve and circulatory support technology. October 2026 brought an approval covering the PASCAL Precision System for tricuspid repair.

Where Things Stand

Yes, on these figures. Edwards Lifesciences (NYSE:EW) recorded a USD 220.2 million non-cash charge for a written-off research asset, while diluted EPS for the quarter inched up to USD 0.53 and sales still grew 10.5%. Growth markers include the Medicare coverage update of September for aortic valve replacement and the newly granted tricuspid approvals. Tariffs, tax and further impairments are the items to monitor against the nine-month Earnings gap. The extract includes no guidance figures, so later filings will be needed to judge the write-off's ongoing effect.